Navigation Links
Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
Date:9/18/2007

ported at least one episode of grade 4 toxicity; the most common grade 4 toxicities were thrombocytopenia (5%) and neutropenia (3%). Fifty percent of patients reported serious adverse events. The most commonly reported serious adverse events were pneumonia (7%), pyrexia (6%), diarrhea (5%), vomiting (4%), and nausea, dehydration, dyspnea and thrombocytopenia (each 3%).

For more information about VELCADE clinical trials, patients and physicians can contact the Millennium Medical Product Information Department at 1-866-VELCADE (1-866-835-2233).

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE, a novel cancer product, and has a robust clinical development pipeline of product candidates. Millennium's research, development and commercialization activities are focused in two therapeutic areas: oncology and inflammation. By applying its knowledge of the human genome, understanding of disease mechanisms and industrialized drug discovery platform, Millennium is developing an exciting pipeline of innovative product candidates. Millennium's website is http://www.millennium.com .

This press release contains "forward-looking statements," including statements about the Company's growth and development of products. Various important risks may cause the Company's actual results to differ materially from the results indicated by these forward-looking statements, including: adverse results in its drug discovery and clinical development programs; failure to obtain patent protection for its discoveries; commercial limitations imposed by patents owned or controlled by third parties; the Company's dependence upon strategic alliance partners to develop and commercialize products and services based on its work; difficulties or delays in obtaining regulatory approvals to market products and services resulting from its development effo
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... -- Harwood Feffer LLP ( www.hfesq.com ) is investigating ... BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: ... fiduciary duties to shareholders or violated the federal securities ... disclosed: "On September 11, 2014, [PDL] was orally notified ... LLP ("EY"), that it was resigning effective September 11, ...
(Date:9/19/2014)... "Copay coupons," a drug manufacturer ... drugs among patients with prescription drug coverage, may now be ... report  from the Department of Health and ... anti-kickback laws prohibit suppliers from offering side-payments to ... the federal government. The report ...
(Date:9/19/2014)... , Sept. 19, 2014 Today, iHealth Lab ... from Xiaomi Ventures, Ltd. for its first institutional round ... continue expanding iHealth,s global reach, accelerate growth and innovation, ... part of the investment, Xiaomi Ventures will join iHealth,s ... of cloud infrastructure and ecommerce. "We are ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of PDL BioPharma, Inc. 2PCMA: New OIG Report Cites Drug Manufacturer "Copay Coupon" Use in Medicare Part D 2iHealth Raises $25 Million to Fuel Growth and Global Market Share 2
... 2011 Brain Plasticity Inc. (BPI), a technology incubator ... that harness the basic principles of brain plasticity to ... disorders, was recently awarded a $2 million grant from ... The grant will fund a two-year clinical trial of ...
... recent paper published in the Journal of Glaucoma ... a fast, objective method to screen for functional damage in ... significantly decreases test duration and provides less subjectivity in evaluating ... out at New York Eye and Ear Infirmary (New York, ...
Cached Medicine Technology:U.S. Department of Defense Awards $2 Million to Brain Plasticity Inc. to Study Impact of Brain Training for Traumatic Brain Injuries 2U.S. Department of Defense Awards $2 Million to Brain Plasticity Inc. to Study Impact of Brain Training for Traumatic Brain Injuries 3New Test to Screen for Glaucoma Damage 2
(Date:9/22/2014)... out to be an old acquaintance: a certain module ... been considered an anchor protein. The researchers report their ... Essential: importing enzymes into peroxisome , Peroxisomes are ... fatty acids and cellular toxins. In order for them ... be imported into the peroxisomes first. The bulk is ...
(Date:9/22/2014)... of more than 30,000 nurses across Europe show that ... more likely to rate the standard of care delivered ... of their hospitals safety and omit necessary patient care. ... and the National Nursing Research Unit (NNRU) at King,s ... 450 hospitals across 12 European countries, was part of ...
(Date:9/22/2014)... Following 14 months of field ... Clearwater Clinical announced the general release of ... for smartphones. ClearSCOPE enables health professionals to capture ... and smartphone. , ENT and Urology specialists developed ... over the cost, encumbrance and slow innovation cycle ...
(Date:9/22/2014)... Thousand Oaks dentist , Dr. Sharon ... Invisalign is a type of orthodontic treatment that can ... can vary based on the extent of the dental ... needed. During this promotion, Dr. Shamoiel is offering complete ... of the adult population has an unhealthy bite, and ...
(Date:9/22/2014)... The invitation only Summit held ... 60 industry executives and thought leaders from major ... Retro Fitness, and Xsport Fitness. Also in attendance ... marketing agencies and private equity investors representing over ... , The Summit highlighted best practices for solving ...
Breaking Medicine News(10 mins):Health News:The accelerator of molecular motors 2Health News:Nurse survey shows longer working hours impact on quality of care 2Health News:ClearSCOPE 2.0 Endoscope Adaptor for Smartphones Announced; Endoscopic Video Capture Reinvented 2Health News:Thousand Oaks Cosmetic Dentist, Sharon Shamoiel DDS, Is Now Offering a Special on Invisalign 2Health News:Motionsoft Concludes Inaugural 2014 Technology Summit 2Health News:Motionsoft Concludes Inaugural 2014 Technology Summit 3
... ARBOR, Mich.---Scientists have discovered a molecular assistant called Spy that ... purposes. Bacteria are widely used to manufacture proteins used ... job. Many proteins fall apart and get cut up inside ... useless tangles instead of folding properly, as they must in ...
... FL 14 February, 2011 Elsevier / MEDai, ... announced today the launch of the latest version of ... The new version will feature an expanded set of ... new predictions: ICU Admission Prediction, Length of Stay Prediction ...
... two pesticides, rotenone and paraquat, and Parkinson,s disease. People ... times more often than non-users. The study ... National Institute of Environmental Health Sciences (NIEHS), which is ... Parkinson,s Institute and Clinical Center in Sunnyvale, Calif. ...
... 11 (HealthDay News) -- The U.S. Food and Drug ... that provides three-dimensional images of the breast for cancer ... an upgrade to Massachusetts-based Hologic Inc.,s FDA-approved two-dimensional system, ... breasts. The 3-D images may help physicians more accurately ...
... , SUNDAY, Feb. 13 (HealthDay News) -- People who ... may be protecting themselves from developing Parkinson,s disease, a ... are found in a variety of foods such as ... touted as protective against some diseases because of their ...
... News) -- Hunters who use tree stands can stay safe ... a study on tree stand safety. The reminder comes ... from tree stands and four died during the recent deer-hunting ... falls in Alabama in a single year, said the state,s ...
Cached Medicine News:Health News:Quest for designer bacteria uncovers a 'Spy' 2Health News:Elsevier/MEDai enhances real-time clinical surveillance system for hospitals 2Health News:NIH study finds 2 pesticides associated with Parkinson's disease 2Health News:FDA Approves First 3D Mammogram Device 2Health News:Berries May Offer Sweet Protection Against Parkinson's Disease 2Health News:Berries May Offer Sweet Protection Against Parkinson's Disease 3Health News:Spate of Hunter Injuries Spurs New Call for Tree Stand Safety 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: